WuXi XDC Cayman Inc (HKSE:02268) Share Price

Company Profile

Business description
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
Contact
No. 11 Xinhui Ring Road
Xinwu
Jiangsu Province
Wuxi
CHN
https://www.wuxixdc.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,041

Recommended

In exchange for an export license to China the chip makers will pay the US government 15% of revenue.

Brian Colello, CPA | 11 August 2025

Shares of Berkshire have plunged more than 12% since May.

Sarah Hansen | 11 August 2025

Stellar first half profits but increasing competition will lower future rate increases.

Nathan Zaia | 11 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,117.60	41.00	0.45%
CAC 40	7,698.52	44.48	-0.57%
DAX 40	24,081.34	81.52	-0.34%
Dow JONES (US)	43,975.09	200.52	-0.45%
FTSE 100	9,129.71	33.98	0.37%
HKSE	24,906.81	47.99	0.19%
NASDAQ	21,385.40	64.62	-0.30%
Nikkei 225	41,820.48	761.33	1.85%
NZX 50 Index	12,911.86	67.23	0.52%
S&P 500	6,373.45	16.00	-0.25%
S&P/ASX 200	8,844.80	37.70	0.43%
SSE Composite Index	3,647.55	12.42	0.34%